Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CDXS - Codexis, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.00
DETAILS
HIGH:
$5.00
LOW:
$5.00
MEDIAN:
$5.00
CONSENSUS:
$5.00
UPSIDE:
199.40%
Stock News
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.
Codexis Q2 Earnings Call Highlights
Codexis NASDAQ: CDXS reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.
Codexis Reports Second Quarter 2026 Financial Results
Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA Completed successful equity capital raise of approximately $25 million in net proceeds REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the second quarter ended June 30, 2026, and provided a business update.
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the appointment of David Butler, PhD, to its Strategic Advisory Board (SAB).
Codexis to Report Second Quarter 2026 Financial Results on August 11
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2026 on Tuesday, August 11, 2026, following the close of market.
Codexis: ECO Synthesis And Runway Reset Warrant An Upgrade (Rating Upgrade)
CDXS is now shifting toward differentiated enzymes and ECO Synthesis, which I think could pay off as commoditized small molecules become less attractive. We've now seen a customer manufacturing order, as well as CDMO evaluations that validate there's interest in CDXS's offerings. However, I concede that this bull case remains inherently speculative until we see recurring commercial demand or larger contracts.
Codexis Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $1.50 per share. Net proceeds to Codexis from the offering are expected to be approximately $23.1 million after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about July 27, 2026, subject to customary closing conditions. Codexis has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 2,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
Codexis Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Codexis. In addition, Codexis intends to grant to the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering, on the same terms. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the size or terms of the offering.
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.25 per share a year ago.
Codexis Reports First Quarter 2026 Financial Results
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis to share RNA manufacturing advances at TIDES USA
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO Synthesis® Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14 at the Hynes Convention Center in Boston.
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
Codexis, Inc. delivered strong FY25 results, with revenue up 19% to $70.4M, driven by a $37.8M technology transfer agreement with Merck. CDXS's ECO Synthesis platform targets the expanding siRNA/RNA therapeutics market, offering scalable, high-margin enzymatic manufacturing as a disruptive alternative to chemical synthesis. Operational improvements included gross margin expansion to 64%, narrowed net loss, and SG&A expense reductions, positioning CDXS for financial sustainability.
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
Codexis shares jumped 37.8% in after-hours trading after the company reported a profitable fourth quarter and full-year 2025 revenue growth.
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Codexis (CDXS) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.13 per share a year ago.
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update.